Alterations in the serum proteome profile during the development of ovarian cancer

Sun,Liping; Li,Li; Li,Zhao; Hong,Shuhui; Yang,Qifeng; Qu,Xun; Kong,Beihua

doi:10.3892/ijo.2014.2675

Alterations in the serum proteome profile during the development of ovarian cancer

Authors:
- Liping Sun
- Li Li
- Zhao Li
- Shuhui Hong
- Qifeng Yang
- Xun Qu
- Beihua Kong
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China, Department of Obstetrics and Gynecology, Qianfoshan Hospital, Shandong University, Jinan, Shandong 250012, P.R. China, The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, New Brunswick, NJ 08903, USA, Department of Basic Medicine, Shandong University, Jinan, Shandong 250012, P.R. China
Published online on: September 25, 2014 https://doi.org/10.3892/ijo.2014.2675
Pages: 2495-2501

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ovarian cancer causes more deaths than any other malignant tumor of the female reproductive system. This is because the condition usually goes undetected until the late stages. The purpose of the present study is to identify alterations in the serum proteome profile during the development of ovarian cancer and to provide an experimental basis for discovering new and valuable serum biomarkers for the early detection of ovarian carcinoma. Surface-enhanced laser desorption/ionization-time of flight (SELDI-TOF-MS) was used to profile changes in the serum proteome of Fischer 344 rats with ovarian cancer during the progress of tumor development. Sera were collected from the rats on day A (1 week before injection of tumor cells), day B (4 weeks after injection), and day C (6 weeks after injection). Each sample was subjected to SELDI-TOF-MS testing. Peak detection and alignment and selection of peaks with the highest discriminatory power were performed using proteinchip biomarker software. Decision tree analyses were performed using biomarker pattern software. Finally, 3 peaks were found to be the most valuable ones (3759, 4659 and 9318 Da). The expression frequency of m/z 3759-Da peaks was downregulated and another two frequencies (4659 and 9318 Da) were upregulated, and the levels of expression of these three proteins showed the same tendency as the expression frequency during the development of ovarian cancer. The total accuracy rate of diagnosis at 4 and 6 weeks post-injection was 94.7 and 97.3%, respectively. Profiling the serum proteome changes during the process of the cancer development using SELDI-TOF-MS may provide useful information regarding carcinogenesis and facilitate discovery of novel serum biomarkers for early detection.

View Figures

View References

1	Maheedhar K, Bhat RA, Malini R, et al: Diagnosis of ovarian cancer by Raman spectroscopy: a pilot study. Photomed Laser Surg. 26:83–90. 2008. View Article : Google Scholar : PubMed/NCBI
2	Wegdam W, Moerland PD, Meijer D, et al: A critical assessment of SELDI-TOF-MS for biomarker discovery in serum and tissue of patients with an ovarian mass. Proteome Sci. 10:452012. View Article : Google Scholar : PubMed/NCBI
3	Tessitore A, Gaggiano A, Cicciarelli G, et al: Serum biomarkers identification by mass spectrometry in high-mortality tumors. Int J Proteomics. 2013:1258582013. View Article : Google Scholar : PubMed/NCBI
4	Kristjansdottir B, Levan K, Partheen K, Carlsohn E and Sundfeldt K: Potential tumor biomarkers identified in ovarian cyst fluid by quantitative proteomic analysis, iTRAQ. Clin Proteomics. 10:42013. View Article : Google Scholar : PubMed/NCBI
5	Sarojini S, Tamir A, Lim H, et al: Early detection biomarkers for ovarian cancer. J Oncol. 2012:7090492012. View Article : Google Scholar : PubMed/NCBI
6	Kamai T, Tomosugi N, Abe H, Kaji Y, Oyama T and Yoshida K: Protein profiling of blood samples from patients with hereditary leiomyomatosis and renal cell cancer by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. Int J Mol Sci. 13:14518–14532. 2012. View Article : Google Scholar
7	Liu C: The application of SELDI-TOF-MS in clinical diagnosis of cancers. J Biomed Biotechnol. 2011:2458212011.PubMed/NCBI
8	Kelly P, Paulin F, Lamont D, et al: Pre-treatment plasma proteomic markers associated with survival in oesophageal cancer. Br J Cancer. 106:955–961. 2012. View Article : Google Scholar : PubMed/NCBI
9	Simsek C, Sonmez O, Keyf AI, et al: Importance of serum SELDI-TOF-MS analysis in the diagnosis of early lung cancer. Asian Pac J Cancer Prev. 14:2037–2042. 2013. View Article : Google Scholar : PubMed/NCBI
10	Opstal-van Winden AW, Krop EJ, Karedal MH, et al: Searching for early breast cancer biomarkers by serum protein profiling of pre-diagnostic serum; a nested case-control study. BMC Cancer. 11:3812011.PubMed/NCBI
11	Gast MC, van Dulken EJ, van Loenen TK, et al: Detection of breast cancer by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry tissue and serum protein profiling. Int J Biol Markers. 24:130–141. 2009.PubMed/NCBI
12	Seibert V, Ebert MP and Buschmann T: Advances in clinical cancer proteomics: SELDI-TOF-mass spectrometry and biomarker discovery. Brief Funct Genomic Proteomic. 4:16–26. 2005. View Article : Google Scholar : PubMed/NCBI
13	Giusti I, D’Ascenzo S and Dolo V: Microvesicles as potential ovarian cancer biomarkers. Biomed Res Int. 2013:7030482013. View Article : Google Scholar : PubMed/NCBI
14	Wiesner A: Detection of tumor markers with ProteinChip technology. Curr Pharm Biotechnol. 5:45–67. 2004. View Article : Google Scholar : PubMed/NCBI
15	Mu AK, Lim BK, Hashim OH and Shuib AS: Identification of O-glycosylated proteins that are aberrantly excreted in the urine of patients with early stage ovarian cancer. Int J Mol Sci. 14:7923–7931. 2013.
16	Callesen AK, Mogensen O, Jensen AK, et al: Reproducibility of mass spectrometry based protein profiles for diagnosis of ovarian cancer across clinical studies: a systematic review. J Proteomics. 75:2758–2772. 2012. View Article : Google Scholar : PubMed/NCBI
17	Emanuele VA II, Panicker G, Gurbaxani BM, Lin JM and Unger ER: Sensitive and specific peak detection for SELDI-TOF mass spectrometry using a wavelet/neural-network based approach. PLoS One. 7:e481032012. View Article : Google Scholar : PubMed/NCBI
18	Diao L, Clarke CH, Coombes KR, et al: Reproducibility of SELDI spectra across time and laboratories. Cancer Inform. 10:45–64. 2011.PubMed/NCBI
19	Wang J, Zhang X, Ge X, Guo H, Xiong G and Zhu Y: Proteomic studies of early-stage and advanced ovarian cancer patients. Gynecol Oncol. 111:111–119. 2008. View Article : Google Scholar : PubMed/NCBI
20	Zhang H, Kong B, Qu X, Jia L, Deng B and Yang Q: Biomarker discovery for ovarian cancer using SELDI-TOF-MS. Gynecol Oncol. 102:61–66. 2006. View Article : Google Scholar : PubMed/NCBI
21	Zhang Z, Bast RC Jr, Yu Y, et al: Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 64:5882–5890. 2004. View Article : Google Scholar : PubMed/NCBI
22	Moshkovskii SA, Serebryakova MV, Kuteykin-Teplyakov KB, et al: Ovarian cancer marker of 11.7 kDa detected by proteomics is a serum amyloid A1. Proteomics. 5:3790–3797. 2005. View Article : Google Scholar : PubMed/NCBI
23	Cao XL, Li H, Yu XL, et al: Predicting early intrahepatic recurrence of hepatocellular carcinoma after microwave ablation using SELDI-TOF proteomic signature. PLoS One. 8:e824482013. View Article : Google Scholar : PubMed/NCBI
24	Qian JY, Mou SH and Liu CB: SELDI-TOF MS combined with magnetic beads for detecting serum protein biomarkers and establishment of a boosting decision tree model for diagnosis of pancreatic cancer. Asian Pac J Cancer Prev. 13:1911–1915. 2012. View Article : Google Scholar : PubMed/NCBI
25	NCCN. NCCN Clinical Guidelines in Oncology: Ovarian Cacer Including Fallopian Tube Cancer and Primary Peritoneal Cancer (Vesion 1.2014). 2014.
26	Vlasova MA, Moshkovskii SA, Safarova MP, Makarov OV and Archakov AI: Molecular diagnostics of ovarian cancer using proteome techniques. Biomed Khim. 51:367–383. 2005.(In Russian).
27	Huijbers A, Velstra B, Dekker TJ, et al: Proteomic serum biomarkers and their potential application in cancer screening programs. Int J Mol Sci. 11:4175–4193. 2010. View Article : Google Scholar : PubMed/NCBI
28	De Bock M, de Seny D, Meuwis MA, et al: Challenges for biomarker discovery in body fluids using SELDI-TOF-MS. J Biomed Biotechnol. 2010:9060822010.PubMed/NCBI
29	Cadron I, Van Gorp T, Amant F, et al: The use of laser microdis-section and SELDI-TOF MS in ovarian cancer tissue to identify protein profiles. Anticancer Res. 29:1039–1045. 2009.PubMed/NCBI
30	Luo J, Qian JH, Yu JK, Zheng S, Xie X and Lu WG: Discovery of altered protein profiles in epithelial ovarian carcinogenesis by SELDI mass spectrometry. Eur J Gynaecol Oncol. 29:233–238. 2008.PubMed/NCBI
31	Toss A, De Matteis E, Rossi E, et al: Ovarian cancer: can proteomics give new insights for therapy and diagnosis? Int J Mol Sci. 14:8271–8290. 2013. View Article : Google Scholar : PubMed/NCBI
32	Sinha A, Ignatchenko V, Ignatchenko A, Mejia-Guerrero S and Kislinger T: In-depth proteomic analyses of ovarian cancer cell line exosomes reveals differential enrichment of functional categories compared to the NCI 60 proteome. Biochem Biophys Res Commun. 445:694–701. 2014. View Article : Google Scholar : PubMed/NCBI